Dow Down1.10% Nasdaq Down1.82%

Alimera Sciences, Inc. (ALIM)

2.17 Down 0.03(1.36%) Feb 8, 4:00PM EST
|After Hours : 2.17 Up 0.00 (0.02%) Feb 8, 4:59PM EST
ProfileGet Profile for:
Alimera Sciences, Inc.
6120 Windward Parkway
Suite 290
Alpharetta, GA 30005
United States - Map
Phone: 678-990-5740
Fax: 678-990-5744

Index Membership:N/A
Industry:Drug Manufacturers - Major
Full Time Employees:70

Business Summary 

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. The company focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient’s eye to a placement site that uses the eye’s natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide (FAc). It has license agreements with pSivida US, Inc. for the development and sale of ILUVIEN, and a delivery device to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans (other than uveitis) or to treat DME. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Alimera Sciences, Inc.

Corporate Governance 
Alimera Sciences, Inc.’s ISS Governance QuickScore as of Feb 1, 2016 is 9. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 8; Compensation: 10.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Charles Daniel Myers , 62
Co-Founder, Chief Exec. Officer and Director
Mr. Richard S. Eiswirth Jr., 48
Pres and Chief Financial Officer
Mr. David R. Holland , 52
Co-Founder and Sr. VP of Sales & Marketing
Dr. Kenneth Green Ph.D., 58
Chief Scientific Officer and Sr. VP
Mr. Philip Ashman Ph.D., 51
Sr. VP and European Managing Director
Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders